Literature DB >> 11054214

Surgical treatment of venous malformations in Klippel-Trénaunay syndrome.

A A Noel1, P Gloviczki, K J Cherry, T W Rooke, A W Stanson, D J Driscoll.   

Abstract

PURPOSE: Klippel-Trénaunay syndrome (KTS) is a complex congenital anomaly, characterized by varicosities and venous malformations (VMs) of one or more limbs, port-wine stains, and soft tissue and bone hypertrophy. Venous drainage is frequently abnormal because of embryonic veins, agenesis, hypoplasia, valvular incompetence, or aneurysms of deep veins. We previously reported on the surgical management of KTS. In this article, we update our experience.
METHODS: Twenty patients with KTS underwent surgical treatment for VMs between July 1, 1987, and January 1, 2000. This group represented 6.9% of 290 patients with KTS who were seen at our institution during this 12.5-year study period. Surgical indications, venous anatomy (determined with duplex scan, contrast phlebography, magnetic resonance imaging or magnetic resonance phlebography), operative procedures, and complications were reviewed, and outcomes were recorded.
RESULTS: Twelve male and eight female patients (mean age, 23.4 years; range, 7.7-40.6 years) underwent 30 vascular surgical procedures in 21 lower limbs. All 20 patients (100%) had varicose veins or VMs, 13 (65%) had port-wine stains, and 18 (90%) had limb hypertrophy. Pain was the most common complaint, which was present in 16 patients (80%), followed by swelling in 15 (75%), bleeding in 8 (40%), and superficial thrombophlebitis and cellulitis in 3 (15%). Imaging confirmed patent deep veins in 18 patients, hypoplastic femoral vein in 1, and entrapped popliteal veins bilaterally in 1. Four patients (20%) had large persistent sciatic veins (PSVs). The CEAP clinical classification was C-3 for 17 patients (85%), C-4 for 1 patient (5%), and C-6 for 2 patients (10%). Stripping of large lateral veins, avulsion, and excision of varicosities or VMs were performed on all limbs. Three patients required staged resections. The release of entrapped popliteal veins was performed in both limbs of one patient; another underwent a popliteal-saphenous bypass graft. One patient underwent excision of a PSV. Open and endoscopic perforator vein ligation was performed in one patient each. Two patients (12%) had hematomas that required evacuation. No patients had caval filter placement; none had postoperative deep venous thrombosis or pulmonary embolus. The mean follow-up was 63.6 months (range, 0-138 months). All patients reported initial improvement, but some varicosities recurred in 10 patients (50%), an ulcer did not heal in one, and a new ulcer developed in one, 8 years after surgery. Three patients underwent reoperation for recurrent varicosities. Follow-up CEAP scores were C-2 in 10 patients (50%), C-3 in 6 patients (30%), C-4 and C-5 in 1 patient each (5%), and C-6 in 2 patients (10%). Clinical scores improved from 4.3 +/- 2.2 to 3.1 +/- 2.3. (P =.03).
CONCLUSIONS: The management of patients with KTS continues to be primarily nonoperative, but those patients with patent deep veins can be considered for excision of symptomatic varicose veins and VMs. Although the recurrence rate is high, clinical improvement is significant, and reoperations can be performed if needed. Occasionally, deep vein reconstruction, excision of PSVs, or subfascial endoscopic perforator surgery is indicated. Because KTS is rare, patients should receive multidisciplinary care in qualified vascular centers.

Entities:  

Mesh:

Year:  2000        PMID: 11054214     DOI: 10.1067/mva.2000.110343

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  27 in total

Review 1.  Female Pelvic Vascular Malformations.

Authors:  Aparna Annam
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

2.  Klippel-Trenaunay Syndrome: a case report with brief review of literature.

Authors:  Mohammad Iqbal Zea; Mohammad Hanif; Mohammad Habib; Ahmed Ansari
Journal:  J Dermatol Case Rep       Date:  2009-12-30

3.  Port wine stain, soft tissue bone hypertrophy and leg ulcer.

Authors:  Aleksandar Jankovic; Ivana Binic; Milenko Stanojevic
Journal:  BMJ Case Rep       Date:  2009-05-21

Review 4.  Life-threatening bleeding after tooth extraction due to vascular malformation: a case report and literature review.

Authors:  Marcus Stephan Kriwalsky; Dimitrios Papadimas; Peter Maurer; Martin Brinkmann; Jochen Jackowski; Martin Kunkel
Journal:  Oral Maxillofac Surg       Date:  2014-04-23

Review 5.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

6.  Closure of non-healing chronic ulcer in Klippel-Trenaunay syndrome using low-level laser therapy.

Authors:  Snehil Dixit; Arun G Maiya; Shashikiran Umakanth; Barkur A Shastry
Journal:  BMJ Case Rep       Date:  2012-06-14

7.  Focal venous hypertension as a pathophysiologic mechanism for tissue hypertrophy, port-wine stains, the Sturge-Weber syndrome, and related disorders: proof of concept with novel hypothesis for underlying etiological cause (an American Ophthalmological Society thesis).

Authors:  Cameron F Parsa
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

8.  Control of disseminated intravascular coagulation in Klippel-Trenaunay-Weber syndrome using enoxaparin and recombinant activated factor VIIa: a case report.

Authors:  Ulf H Beier; Mary Lou Schmidt; Howard Hast; Susan Kecskes; Leonard A Valentino
Journal:  J Med Case Rep       Date:  2010-03-19

9.  Klippel-trenaunay syndrome: an often overlooked risk factor for venous thromboembolic disease.

Authors:  Albert Ndzengue; Richard B Rafal; Simon Balmir; Dinker B Rai; Eric A Jaffe
Journal:  Int J Angiol       Date:  2012-12

10.  Parkes Weber or Klippel-Trenaunay syndrome? Non-invasive diagnosis with MR projection angiography.

Authors:  S Ziyeh; J Spreer; J Rössler; R Strecker; A Hochmuth; M Schumacher; J Klisch
Journal:  Eur Radiol       Date:  2004-03-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.